(Q36319330)

13 August 2017

1 reference

title

Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action (English)

1 reference

13 August 2017

main subject

cardiovascular disease

1 reference

1 reference

2

Nikolaus Marx

1 reference

13 August 2017

Daniel Walcher

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Diabetes and Vascular Disease Research

13 August 2017

published in

1 reference

13 August 2017

volume

1

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

76-81

1 reference

Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Rosiglitazone Lowers Blood Pressure and Increases Arterial Compliance in Postmenopausal Women With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Insulin resistance as a major determinant of increased coronary heart disease risk in postmenopausal women with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Clinical utility of endothelial function testing: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Insulin resistant young subjects at risk of accelerated atherosclerosis exhibit a marked reduction in peripheral endothelial function early in life but not differences in intima-media thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Peroxisome proliferator-activated receptor gamma and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Adipokines, inflammation, and the endothelium in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Pulmonary edema associated with rosiglitazone and troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Thiazolidinedione-induced edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2004.011

21 January 2018

Identifiers

DOI

10.3132/DVDR.2004.011

1 reference

13 August 2017

1 reference